Newsfeeds - Spark Newswire

Cantor Fitzgerald analyst Charles Duncan maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Overweight and raises the price target from $28 to $33.

ACAD

1 minute read

Acadia Pharma’s Rett Syndrome Drug Becomes First FDA-Approved Treatment

By Vandana Singh

Today, 5:35 PM

The FDA has approved Acadia Pharmaceuticals Inc’s (NASDAQ:ACAD) Daybue (trofinetide) for Rett syndrome in adult and pediatric patients two years of…

ACAD

1 minute read

Mizuho Reiterates Neutral on ACADIA Pharmaceuticals, Maintains $19 Price Target

By Benzinga Newsdesk

Today, 5:35 PM

Mizuho analyst Uy Ear reiterates ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Neutral and maintains $19 price target.

ACAD

1 minute read

Citigroup Maintains Neutral on ACADIA Pharmaceuticals, Raises Price Target to $19.4

By Benzinga Newsdesk

Today, 5:35 PM

Citigroup analyst Neena Bitritto-Garg maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Neutral and raises the price target from $19 to $19.4.

ACAD

1 minute read

Oppenheimer Maintains Perform on ACADIA Pharmaceuticals, Raises Price Target to $17

By Benzinga Newsdesk

Today, 5:35 PM

Oppenheimer analyst Jay Olson maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Perform and raises the price target from $16 to $17.

ACAD

1 minute read

Citigroup Maintains Neutral on ACADIA Pharmaceuticals, Raises Price Target to $19

By Benzinga Newsdesk

Today, 5:35 PM

Citigroup analyst Neena Bitritto-Garg maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Neutral and raises the price target from $17 to $19.

ACAD

1 minute read

Acadia Pharmaceuticals Highlights Publication Of NUPLAZID analysis In Drug Safety

By Bill Haddad

Today, 5:35 PM

Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) announced today that the journal Drug Safety published results from a retrospective analysis finding a lower mortality risk in patients with Parkinson's disease

ACAD